BioSpace News Archive

Inotrem, an advanced clinical stage biotech company specialized in immunotherapies targeting the TREM-1 pathway, announced the appointment of Dr. Gregory Meiffren as Project Director for its Antibody-based R&D Program.

Antengene Corporation Limited announced the acceptance of an abstract at the upcoming 2021 American Society of Hematology Annual Meeting, which will be held from December 11-14, 2021, both in Atlanta, Georgia, and virtually at https://www.hematology.org/meetings/annual-meeting.

Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates targeting cancers in areas of high unmet medical need, reported financial results for the third quarter ended September 30, 2021 and provided a business update.

MannKind Corporation, a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced the closing on November 8, 2021, of its previously announced sale-leaseback transaction with an affiliate of Creative Manufacturing Properties.

Haemonetics Corporation announced that financial results for its second quarter fiscal 2022, which ended October 2, 2021, are available on its Investor Relations website.

Clene Reports Third Quarter 2021 Operating and Financial Highlights

Artificial intelligence tools and technologies have been making enormous impacts on various aspects of healthcare.

The current generation of infusion pumps is current equipped with software to control the entire pumping mechanism, with the dual objective of safety and ease-of-use.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies London Healthcare Conference, taking place in-person and virtually from 16 to 19 November 2021.

In simple words, apoptosis assays refers to programmed cell deaths, which are able to regulate genetically cell ablation over the period of normal development.